Study: Anti-NGF drug could be effective treatment for OA patients

04/16/2013 | InternalMedicineNews.com (free registration)

Treatment of osteoarthritis of the hip with tanezumab, an anti-nerve growth factor, was found to significantly improve pain and physical function after 16 weeks, according to results from a Phase III study of 621 patients with painful hip OA. According to the study, tanezumab could be useful in treating OA patients who can't tolerate or don't respond to nonopioid treatments.

View Full Article in:

InternalMedicineNews.com (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
In house Compliance Officer
Confidential
Pompano Beach, FL
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC